Efficacy of Qizi Yusi Pill on Pregnancy Outcomes in Women of Advanced Reproductive Age: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
10.1007/s11655-022-3515-2
- Author:
Yi ZHANG
1
;
Yan QIAO
1
;
Li LI
2
;
Dan-Dan GAO
1
;
Jing-Yan SONG
2
;
Zhen-Gao SUN
3
Author Information
1. College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.
2. The First Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, 250014, China.
3. Reproductive and Genetic Center of Integrated Medicine, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, China. sunzhengao77@126.com.
- Publication Type:Randomized Controlled Trial
- Keywords:
Qizi Yusi Pills;
advanced age;
in vitro fertilization-embryo transfer;
randomized controlled trial
- MeSH:
Drugs, Chinese Herbal/therapeutic use*;
Embryo Transfer;
Female;
Fertilization in Vitro;
Gonadotropin-Releasing Hormone/agonists*;
Humans;
Ovulation Induction;
Pregnancy;
Pregnancy Outcome;
Pregnancy Rate
- From:
Chinese journal of integrative medicine
2022;28(8):675-682
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To evalvate efficacy of Qizi Yusi Pills (QYP), a Chinese medicine compound preparation, on in vitro fertilization-embryo transfer (IVF-ET) in women of advanced reproductive age.
METHODS:This multicenter, randomized, double-blind, placebo-controlled trial was conducted from June 2018 to October 2019. A total of 124 patients were randomly allocated to either the QYP group or the placebo group using a stratified block randomization design, with 62 patients in each group. All patients completed controlled ovarian stimulation using a standard gonadotropin-releasing hormone agonist (GnRH-a) long protocol. As the QYP group, QYP was administered while the control group received placebo. QYP and placebo were administered for a total of 24 to 30 days from the day of GnRH-a pituitary downregulation to transvaginal oocyte retrieval. Both medications were taken orally at doses of 10 g three times each day. The primary outcome was cumulative pregnancy rate, and the secondary outcomes were periodic medication, follicular status, serum hormone and endometrial receptivity. Follow-up continued until 4 weeks after delivery. Maternal and neonatal complications, such as gestational diabetes, were also observed.
RESULTS:Overall, 119 patients completed the study, 60 in the QYP group and 59 in the placebo group. Per protocol (PP) analysis revealed that 6-month cumulative pregnancy rate in the QYP group was significantly higher than that in the placebo group [43.33% (26/60) vs. 25.42% (15/59), P=0.040). Additionally, more oocytes were retrieved from the QYP group than those from the placebo group (8.95 ± 3.12 vs. 7.85 ± 1.91, P=0.022). Moreover, the endometrial thickness of HCG day in the QYP group was significantly higher than that in the placebo group (11.78 ± 2.27 mm vs. 10.68 ± 2.07 mm, P=0.012). Maternal and neonatal complications between the two groups were not significantly different (P>0.05). Intention-to-treat analysis was in line with PP results.
CONCLUSIONS:QYP can enhance ovarian reserve capacity and ovarian response, and possibly promote endometrial receptivity. QYP effectively improves cumulative pregnancy rates in older patients (⩾35 years) undergoing IVF-ET. (Registration No. ChiCTR1800014427).
